Retatrutide

Description

Retatrutide is one of the important metabolic drugs currently available, a synthesised triple agonist that activates GLP-1, GIP, and glucagon receptors at the same time. It makes Retatrutide different from dual agonists such as tirzepatide, thus prompting the drug to be tested for obesity and type 2 diabetes clinical trials, hence becoming a very documented compound for metabolic research programs.

It is a 5mg to 40mg vial in lyophilised powder form with purity ≥98%. It can be used for weight management, glucose metabolism, lipids, and fatty liver accumulation research. Store at -20°C under appropriate laboratory conditions. For laboratory and in vitro research use only. 

Product Features:  

• Five vial sizes: 10mg, 20mg and 30mg
• Purity: ≥98% HPLCAssay  
• CAS number: 2381272-89-3 
• Agonist of triple receptors: GLP-1, GIP & Glucagonreceptors